Medication Monitor

Generic Name (Trade Name—Company)
September 20, 2019


(Taltz—Eli Lilly)
Ixekizumab has new indication for treatment of active ankylosing spondylitis

On August 26, FDA approved ixekizumab injection 80 mg/mL to treat adults with active ankylosing spondylitis, also known as radiographic axial spondyloarthritis.

This is the third indication for ixekizumab, which was first approved in March 2016 for treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. It was then approved by FDA in December 2017 to treat adults with active psoriatic arthritis.

The drug is a humanized interleukin-17A antagonist. The recommended dosage is 160 mg by S.C. injection (two 80-mg injections), followed by 80 mg every 4 weeks.

Adverse effects include injection site reactions, upper respiratory tract infections, nausea, and tinea infections.

The prescribing info includes warnings and precautions not to use in patients with a previous serious hypersensitivity, such as anaphylaxis, to ixekizumab or any of the excipients. The drug may increase the risk of infection.

Patients should be evaluated for tuberculosis, hypersensitivity, inflammatory bowel disease, and immunizations before treatment initiation.